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Introduction
The World Health Organisation pinpoints brain disorders
as ‘one of the greatest threats to public health’ (World
Health Organisation, 2006), with one in four people
affected by neurological or mental health conditions at
some point in their lives (World Health Organisation,
2001). However, there is currently a dearth of treatments
for these disorders. Translational neuroscience aims to re-
solve this by transforming knowledge gained from basic
science into interventions and applications for treating
human disease.
To understand why past decades of research have failed
to result in successful treatments, we must understand what
translational neuroscience is and how to effectively achieve
it. Classically, translational neuroscience has taken the form
of a ‘bench-to-bedside’ model, whereby laboratory research
(‘bench’) directly informs the development of novel treat-
ments or technologies in the clinic (‘bedside’). However,
this model is reductive and neglects that translational neu-
roscientific research is cyclical, involving both wet and dry
laboratory research, research culture, industry partners, the
public and policy makers. In this article, we discuss the cur-
rent landscape of translational neuroscience and the factors
that influence its success in leading to novel treatments in
the clinic.
Wet lab
At the core of translational neuroscience is the ‘wet’ la-
boratory research, which aims to understand underlying
disease mechanisms and how they can be targeted for
therapeutic purposes. One explanation for why this re-
search has struggled to translate into the clinic may be
the difficulty in studying the human brain in a laboratory
setting. This is presently done using a medley of models
from animals to human cells and post-mortem tissue;
however, each is subject to inherent limitations in their
availability, complexity and ability to recapitulate human
brain function.
One of the most commonly used models for preclinical
research is small rodents, mainly mice and rats. However,
whilst animal models are indispensable for studying the
intact, live nervous system, rodents lack the complexity
of the human brain and do not fully recapitulate complex
human disease. This is evident for instance in the field of
Alzheimer’s research, where no single rodent model per-
fectly mimics all pathology seen in patients (Götz et al.,
2018). However, these models are continuously improv-
ing, and are useful for studying specific disease processes:
for instance, transgenic mice and rats have been instru-
mental in understanding specific pathomechanisms of
Alzheimer’s disease (Götz et al., 2018), and were key in
demonstrating the effectiveness of the antisense oligo-
nucleotide therapy Spinraza before it moved onto clinical
trials for spinal muscular atrophy (Corey, 2017).
A promising development for the field of translational
neuroscience has been the advent of human induced
pluripotent stem cell technology. This has been gaining
popularity as a disease model, as it allows researchers to
study dynamic disease processes in live human cells with
practically unlimited material. This is in contrast to post-
mortem studies or resection of live human brain tissue,
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both of which are highly informative of human brain
function and disease, but much more limited in availabil-
ity and modifiability. Furthermore, compared to rodents,
human induced pluripotent stem cells provide a better
tool for studying complex polygenic disease. However,
human induced pluripotent stem cell-derived brain cells
and organoids do not capture the complexity of the
human brain, and similar to rodents are best used as a
tool for studying specific disease processes.
In the absence of a ‘perfect’ model, the best approach
is therefore to combine existing models in an attempt to
increase the translatability of results. However, in order
to best utilize the models currently available for transla-
tional research we need to understand the extent to
which they can capture each aspect of disease. This not
only requires a deep understanding of disease mechanisms
seen in patients but also of the human brain and its func-
tional diversity in general. This need for basic neurosci-
ence research as a basis for translation is clear when
considering the study of glial contributions to disease:
while glia are increasingly recognized as contributing to
neurological disease, glial research is an emerging field
where many questions are only beginning to be answered.
For instance, different subtypes of astrocytes and micro-
glia may differentially contribute to disease; however,
what these subtypes are, and how they differ functionally
from each other, is largely unclear. Furthermore, there is
evidence to suggest that human and rodent glia may have
functional differences (Bedner et al., 2020), but research
into any such differences is limited, and the implications
for using rodent glia for studying human disease remains
unclear. This highlights how successful translation of re-
search into the clinic will require input not only from
translational neuroscientists but also from basic research-
ers aiming to characterize the complexity of the human
brain.
The best approach we therefore have for studying
human disease is to combine the available animal and
human models to best recapitulate the disease process of
interest, as well as to continue developing new models
that may better capture the complexity of the human
brain. However, it is important to bear in mind the limi-
tations of both our current tools as well as our under-
standing of the human brain in trying to narrow the gap
between preclinical research and clinical trial success.
Dry lab
One area of translational neuroscience that is often lost
in the typical bench-to-beside model, is that of ‘dry labs’.
Dry labs typically utilize computational or statistical
approaches to analyse data, encompassing both basic
biology and disease pathology, as well as epidemiological
approaches—addressing why, and to whom, neurological
and psychiatric disorders occur.
In a translational context, examples of the type of out-
put from dry labs include directly biological concepts,
such as the analysis of ‘omics’ for target intervention and
medical imaging for diagnostics. In addition to this, dry
labs enact more overarching approaches such as text min-
ing of health records, and large-scale systematic reviews
and meta-analyses. The latter of these represents a route
by which to amalgamate the outcomes of research and
identify consensuses in the literature, which is crucial to
then facilitate sound, evidence-based clinical decisions.
The reconciliation, synthesis and appraisal of research is
vital for effective translation in the era of the replication
crisis, and when promising preclinical outcomes have
failed to translate to positive results in clinical trials. By
robustly analysing the literature, and systematically
assessing why things have gone wrong, there is scope to
both improve the design, conduct and analysis of neuro-
scientific research, as well as to pinpoint where future
work should be targeted.
Another area of dry lab research that has greatly
expanded in recent years, and offers a promising avenue
for translational outcomes, is the analysis of data accrued
through large-scale cohort studies and biobanks. DNA
sequencing, brain scans, cognitive tests and output from
wearable devices are just some of the data gathered by
these studies, all of which can be analysed with the aim
of delineating disease aetiologies or identifying bio-
markers. Though typically somewhat biased, due to selec-
tion biases and participant attrition, these studies allow
for health data to be scrutinized at a far larger scale than
was previously possible. Additionally, while historically
recruiting presenting patients, studies of specific diseases
have become cognizant of the need to enrol at-risk partic-
ipants in order to understand the therapeutic window for
prophylactics. This is particularly important for condi-
tions with long latencies or prodromal periods such as
Alzheimer’s and Parkinson’s disease. Improved data link-
age to NHS records within these studies is likely to pro-
vide more insight into longitudinal disease trajectories
and allow for feedback from the clinic to be incorporated
into research and analyses. These vast biomedical datasets
ultimately need to be transformed into hypotheses and
knowledge, which relies upon integrating the expertise of
computer scientists and statisticians, with biologists and
neuroscientists. Often there is too large a divide between
these disciplines and leveraging the complementary skills
of both, so tenets of one area are more readily translated
to the other, is likely to expedite robust patient
outcomes.
Each type of work that is conducted in a dry lab rep-
resents an incremental shift towards an outcome in the
clinic, and can both feedback to the wet lab, and feed-
forward to clinical research. For example, identification
of genes associated with diseases and outcomes in
large-scale genome-wide association studies can inform
model organism work, and also feed-forward into pa-
tient stratification or prognostication. The latter of
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these will likely be key in precision medicine and may
lead to breakthroughs in therapeutics that have previ-
ously failed when targeted incorrectly. As with each
area of translational medicine, neuroscientists in dry
labs must keep in mind what is considered a meaning-
ful outcome for the patient—be that feeling, function
or survival—and ultimately target research in this
manner.
Research culture
Whether working in wet or dry lab settings, the working
environment, or ‘culture’, of a research institution has the
potential to promote or prevent the translation of re-
search. One aspect of research culture under increasing
scrutiny is the pressure to publish. With publications
often seen as a form of academic currency, pressure to
publish high quantities of research, quickly, and in high
impact journals, is experienced by many researchers. As
most high impact journals tend to favour novel or news-
worthy findings, in its most extreme form, pressure to
achieve impactful publications can lead to the misrepre-
sentation of data. Examining 20 621 papers published in
40 scientific journals between 1995 and 2014, a 2016
study by Dr. Elisabeth Bik found that 3.8% of papers
contained inappropriate image duplication, and in over
half of these cases the type of image duplication was sug-
gestive of intentional manipulation (Bik et al., 2016).
Whilst the prevalence of intentional misrepresentation of
data in academic publishing is unclear, such cases exem-
plify how pressure to publish contributes to the crisis of
scientific reproducibility. Pressure to publish novel or
news-worthy results also de-incentivises replication studies
that seek to confirm findings, and to validate both new
and well-established methodologies—a key step in the
translational process. The British Neuroscience
Association have recognized that under these pressures,
scientific knowledge is vulnerable to a bias that ‘skews
scientific understanding, contributes to hyped expecta-
tions, and jeopardizes the translation of research to real-
world applications’ (British Neuroscience Association,
2019).
Another way in which research culture can limit the
translational potential of research is via its toll on the
health and wellbeing of researchers. In January this year,
Wellcome published the results of a survey that invited
over 4000 researchers to share their views on research
culture (Wellcome, 2020). Whilst many respondents
viewed their research roles as a vocation, many high-
lighted the proliferation of metrics, multiple commit-
ments, long working hours, lack of diversity and
inclusion, short-term funding and lack of job security as
prominent features of their research environments.
Together with ‘publish or perish’ pressures, these factors
see many committed researchers leave the sector, draining
translational pipelines of skills and expertise.
Increasing awareness of these issues has prompted
responses from organizations such as the Academy of
Medical Sciences, Wellcome and the Medical Research
Council, among others. The British Neuroscience
Association, for example, have launched a Manifesto for
Credibility in Neuroscience (British Neuroscience
Association, 2019), aiming to encourage scientific rigour
and support researchers in challenging damaging practi-
ces. A crucial feature of this manifesto is training in open
science practices: a set of principles and tools that enable
transparent, open and reproducible science (see The
Centre for Open Science: www.cos.io, see also Wilkinson
et al., 2016). Pre-registration of analysis plans via the
open science framework (www.osf.io) or publication of
pre-registered reports, enable researchers to pre-define
their methodologies, minimizing bias during the research
process and, in the case of pre-registered reports, ensuring
publication of results regardless of the outcome. Making
data or code publicly available via secure repositories is
another method of encouraging transparency in the re-
search process, and also enables the validation of empir-
ical work in external samples. Pooling expertise and
making resources open and available fosters collaboration
by bringing together researchers from different groups
within the translational cycle. Platforms such as the open
science framework facilitate collaborative project manage-
ment, and cater for different institutional requirements by
offering features such as embargos on public pre-registra-
tion documents until project completion, which may be
required by industry partners. Upon completion of stud-
ies, manuscripts can be uploaded to pre-print servers
such as biorXiv, medrXiv or the Wellcome Open
Research platform (for those funded by Wellcome), which
make manuscripts publicly available (with a citable digital
object identifier). Pre-registration also prevents manu-
scripts from being held up in the publishing pipeline and
opens them up to informal public review.
Funding bodies and research institutions can affect
positive shifts in research culture from the top down by
incentivizing rigorous scientific practices, committing to
open science principles, valuing leadership skills and
rewarding positive, supportive research environments in
assessment frameworks for funding and career advance-
ment. With this in place, from the bottom up, researchers
will be encouraged to embed open principles in their
work and utilize their expertise in the translational cycle.
Industry
The translation of academic output into novel therapeu-
tics relies on the investment of time and capital from ‘big
pharma’. Pharmaceutical companies are licenced to re-
search, develop, market and distribute drugs. Typically,
the process of drug development takes 10–15 years, gen-
erally includes a combination of in vitro studies, in vivo
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studies and clinical trials, and can cost billions of
pounds.
In recent years, venture capital funding has been pour-
ing into biotechnology companies. This has facilitated a
thriving biotech research and development culture and, in
some cases, has allowed biotech companies to carry out
early-phase clinical trials, increasing their value before ac-
quisition by ‘big pharma’. This model of translating re-
search reduces the risk for pharmaceutical companies and
allows them to invest in a range of therapeutic strategies
and disease areas. The spinal muscular atrophy drug,
Spinraza, is an excellent example of how collaboration
between academia, biotech and pharma can translate re-
search into life-changing therapies. A deep understanding
of the biology of spinal muscular atrophy was developed
in academia, in particular at Cold Spring Harbor
Laboratory and the University of Massachusetts.
Subsequently, Cold Spring Harbor Laboratory and the
biotech company Ionis began collaborating to develop
the therapy. This led to a partnership between Ionis and
the pharmaceutical company Biogen, and in 2015 Biogen
acquired an exclusive licence for the drug. Following suc-
cessful clinical trials, Spinraza was approved by the Food
and Drug Administration and the European Medicines
Agency as the first drug to treat spinal muscular atrophy.
Unfortunately, neuroscientific clinical trial success sto-
ries are few and far between. This has caused pharma-
ceutical giants such as Pfizer, Bristol-Myers Squibb,
GlaxoSmithKline, AstraZeneca and Amgen to steer their
pipelines away from neuroscience despite there being a
huge unmet clinical need. Nevertheless, others such as
Biogen, Takeda, Roche and Johnson & Johnson have
maintained an important presence. The withdrawal of
these major companies from neuroscience research and
development has been a wake-up call for the community.
To incentivize future investments, lessons must be learned
from previous failed trials. A prevalent theory as to why
trials are failing is that there is a lack of understanding
of the mechanisms underlying neurological and psychi-
atric disorders. Perhaps a stronger emphasis on collabor-
ation between industry and academia would ensure that
the capital and project development expertise of ‘big
pharma’ is coupled with deep biological expertise in aca-
demia, and therefore accelerate the understanding of
neurological diseases and mental health conditions.
Another issue may be that outcomes in clinical trials
could be targeted and measured more effectively. To ad-
dress this, companies such as Roche and Takeda are
developing research programmes to collect digital bio-
markers, using smartphones and wearable technology,
from patients and clinical trial participants. These will
provide a more comprehensive and perhaps more sensi-
tive measurement of disease and patient response to
treatment.
An often overlooked contribution of industry to the
translation of research into therapeutics is in providing
researchers with the tools to answer their fundamental
questions. This flywheel of moving research into industry
and injecting innovative technologies back into academia
will be essential in driving impactful, robust neuroscien-
tific research. Once the ground truths of neurological dis-
eases are better understood, and clinical outcomes are
more effectively measured, it will be a matter of time be-
fore pharma substantially reinvest to fulfil the unmet
need of therapeutics for neurological and psychiatric
disorders.
Public engagement
Public engagement is another facet of research and train-
ing through which the translational gap can be narrowed.
The National Co-ordinating Centre for Public
Engagement defines public engagement as: ‘the myriad of
ways in which the activity and benefits of higher educa-
tion and research can be shared with the public’
(National Coordinating Centre for Public Engagement,
2018). This definition encompasses activities such as sci-
ence communication, a largely unidirectional interaction
between researchers and the public, and also bi-direction-
al models such as patient and public involvement (PPI)
and priority setting partnerships.
The words ‘public engagement’ may conjure a peda-
gogical model whereby researchers disseminate informa-
tion to the public through a range of activities: stands at
science festivals, public talks and engaging with the
media. This is regarded as a responsibility of academia,
and it is also a way of effectively communicating public
health messages that are more specific to the brain. There
is plenty of public awareness that smoking damages the
lungs and that eating your ‘5-a-day’ is beneficial for car-
diovascular and metabolic health. But both of these are
also true for the brain. The links between brain health
and these lifestyle factors tend to get left out of public
health messages, a gap which public engagement could
fill.
PPI strategies are common in clinical trials and have
great potential to improve translation. PPI includes
involving patients in developing trial ideas or planning lo-
gistics, which can better take into account participants’
needs. This, in turn, improves enrolment to trials and,
possibly, participant retention in long-term studies
(Crocker et al., 2018). PPI is now also being adopted in
basic science settings. A recent example of this, from the
University of Edinburgh, is the ‘Buddy Pairs’ scheme.
Here, dementia research laboratories were paired with
individuals who had lived experience of dementia (both
patients and carers; Kennedy et al., 2019). The scheme
involved lab tours to facilitate knowledge exchange with-
in these pairs. Visitors with dementia may be curious to
see what a brain looks like with their disease, or about
how their medication works in the brain. By engaging
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with patients, researchers learn that maintaining a higher
level of independence, or delaying disease progression,
are often more important to patients than the develop-
ment of treatments or cures. Interacting with patients
may also provide a powerful motivation for researchers
to continue working in research. As in the clinical trial
setting, PPI is seen as an important part of the strategy
to encourage people to participate in research studies and
to be informed about what their participation enables.
Priority setting partnerships go a step further by pro-
ducing a tangible result from the exchange between stake-
holders. The James Lind Alliance facilitates priority
setting partnerships through a formalized process in
which patients, carers and clinicians, are consulted. This
process involves surveys and workshops in order to con-
verge on the stakeholders’ top 10 priorities. These may
not necessarily be specific research questions but rather
important areas for future research. Much like PPI, the
‘Top 10s’ often challenge preconceptions held by the re-
search community about what is important to patients.
While much research effort is spent on developing a cure,
priorities set in the priority setting partnership may focus
on improving quality of life through earlier diagnosis or
better management of distressing symptoms. As an evi-
dence base in and of themselves, the top 10 priorities are
also a useful resource for justifying funding of research
areas that might otherwise go neglected. For example,
since the Parkinson’s disease priority setting partnership,
published in 2014, the James Lind Alliance reports three
studies into anxiety and depression management in
Parkinson’s disease in response to the priority item:
‘What approaches are helpful for reducing stress and
anxiety in people with Parkinson’s’ (James Lind Alliance,
2014).
Public engagement has the capacity to improve transla-
tion in a number of ways. Dissemination-as-intervention,
with regards to the impact of lifestyle factors on brain
health, is an important supplement to public health mes-
sages that do not usually focus on the brain.
Additionally, by positioning patient groups and carers as
partners in research, public engagement contributes to the
success of trials, reveals novel research opportunities and
fosters positive feeling towards the research community.
Science policy
An often-neglected arm of the translational neuroscience
model is that of science policy, a term with a somewhat
broad definition. Principally, its goal is to consider how
science and technology can best serve the public, and
form and enact public policies accordingly. Whether by
directly implementing research findings into policy-mak-
ing decisions, influencing how certain fields are funded,
or by supporting the translation of emerging technologies,
changes to science policy are powerful means through
which research can shape reality and improve the health
of individuals and populations.
The relationship between research and science policy is
bi-directional; basic and clinical research can inform pub-
lic policies, and research itself can be impacted by policy.
The former is illustrated by the development of special-
ized stroke units in UK hospitals, widely considered a
landmark innovation in stroke care. Annually, more than
100 000 people in the UK experience a stroke. Research
has shown that provision of care in a specialist stroke
unit, versus a general medical ward, reduces rates of
mortality and disability, and enables patients to retain
greater independence post-stroke. This directly translated
into policy, with the Department of Health recommend-
ing major changes to the stroke care system in their
2007 National Stroke Strategy, listing dedicated stroke
units as ‘the single biggest factor that can improve a per-
son’s outcomes following a stroke’ (Department of
Health, 2007). Nonetheless, ensuing research suggests
there remains room for improvement, and sustained en-
gagement with stakeholders and policy makers is vital for
further advances in neurological disorder treatment and
care.
Science policy also impacts research, most notably
through determining allocation of public money for re-
search funding. The more nuanced effects of policy are
embodied by the complex issues surrounding mental
health research and psychoactive substances. In recent
years, novel psychiatric drug development has slowed
and access to psychological interventions is sub-optimal.
Research involving illegal drugs, such as LSD, ketamine,
psilocybin and MDMA, points to their potential as treat-
ment strategies for various mental illnesses (Schenberg,
2018). Although the use of these substances in research is
legal, they remain strictly regulated. Such policies, unfor-
tunately, make working with controlled substances more
challenging. This stymies investigation of clinical efficacy
and mechanistic understanding of their activity. What is
more, the stigma that surrounds their usage potentially
discourages patient engagement and dissuades involve-
ment of researchers, institutions and funders. Policies that
hinder research should be discussed, debated and chal-
lenged, and ultimately the scientific evidence should be
allowed to prevail.
The above examples outline how science policy can
both facilitate and frustrate the translation of research
into meaningful healthcare solutions for the public.
Researchers and their institutions are ideally positioned
to influence public policy and foster better translation.
They possess the expertise crucial for promoting evi-
dence-based policy making and are largely perceived as
knowledgeable, trustworthy and without vested inter-
ests—traits that are sometimes few and far between in
political spheres. Despite this, research findings do not al-
ways form the basis of health-related policies, a phenom-
enon dubbed the ‘research/evidence-policy gap’. A wide
variety of factors contribute to this discordance. Policy
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makers are seldom scientists and are required to make
decisions over short timescales, limiting the amount of in-
formation they can amass and interpret before reaching a
decision. Scientists rarely understand the intricacies of
policy making or how to communicate core information
in a manner that can be readily used by decision makers.
Additionally, existing academic structures do not incentiv-
ize researchers to participate in policy-related processes.
To address the ever-increasing public health and eco-
nomic burden that neurological and psychiatric disorders
present, research must be translated into effective science
policy and researchers should play an active role in this.
As manifested by the success of specialized stroke units,
closer alignment of evidence and political decision-making
has huge potential to improve patient outcomes. This will
not occur without better engagement between all involved
parties and is an area that remains a translation gap for
policy makers and scientists alike.
In summary
The translation of fundamental neuroscientific research
into meaningful clinical outcomes requires an expansion
of the traditional ‘bench-to-bedside model’. The transla-
tional cycle includes academic researchers (from both wet
and dry lab settings), industry partners, individuals with
lived experience of target diseases or disorders, and pol-
icy makers. We have highlighted the necessity of collab-
oration between these groups, who together can identify
appropriate clinical questions, select suitable methodo-
logical approaches and validate them, replicate findings,
develop tools and technologies that drive discovery, and
translate these discoveries into treatments or policy
changes that aim to improve public health. Interactions
between these groups are bi-directional and confer mutual
benefits. The role of research institutions lies at the centre
of this translational cycle. Through the establishment and
maintenance of healthy research cultures, which incentiv-
ize scientific rigour, and support engagement with indus-
try partners, community stakeholders and policy makers,
researchers can more effectively lay the scientific ground-
work required to deliver meaningful clinical outcomes for
those who need them.
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